GlobalData on MSN15d
Mediar Therapeutics signs licensing deal with Eli Lilly for IPF treatment
Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the treatment of IPF.
pulmonaryfibrosisnews3d
MTX-463 expected to enter Phase 2 testing in IPF in first half of 2025
Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.
Lilly signs licensing deal with Mediar for IPF drug
Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into Phase 2 testing for idiopathic pulmonary fibrosis. Mediar said it expects to ...